Deuterated tryptamine derivatives and methods of use
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT 2 receptor.
1. A pharmaceutical composition comprising a compound and a pharmaceutically acceptable vehicle,
wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.
2. The pharmaceutical composition of claim 1 , which is in a liquid dosage form.
3. The pharmaceutical composition of claim 1 , which is in a solid dosage form.
4. The pharmaceutical composition of claim 1 , which is adapted for oral administration.
5. The pharmaceutical composition of claim 1 , which is adapted for intravenous administration.
6. The pharmaceutical composition of claim 1 , which is adapted for subcutaneous administration.
7. The pharmaceutical composition of claim 1 , which is adapted for intramuscular administration.
8. A method of treating a subject with major depressive disorder (MDD), comprising administering to the subject a therapeutically effective amount of a compound, which is:
or a pharmaceutically acceptable salt thereof.
9. A method of treating a subject with treatment-resistant depression (TRD), comprising administering to the subject a therapeutically effective amount of a compound, which is:
or a pharmaceutically acceptable salt thereof.
10. A method of treating a subject with alcohol use disorder, comprising administering to the subject a therapeutically effective amount of a compound, which is:
or a pharmaceutically acceptable salt thereof.